Back to top
more

Illumina (ILMN)

(Delayed Data from NSDQ)

$124.73 USD

124.73
908,797

+2.45 (2.00%)

Updated Apr 29, 2024 04:00 PM ET

After-Market: $124.80 +0.07 (0.06%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value B Growth F Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 30% (76 out of 252)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

Research for ILMN

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

   

0 items in cart

Illumina, Inc. [ILMN]

Reports for Purchase

Showing records 321 - 340 ( 360 total )

Company: Illumina, Inc.

Industry: Medical - Biomedical and Genetics

Record: 321

02/08/2012

Company Report

Pages: 5

4Q11 Results Review: Good End to 2011; Guidance for 2012 Looks Solid; Rejects Roche''s Offer as "Inadequate"

Provider: AURIGA USA

Analyst: MCDONALD P

Price: 10.00

Research Provided by a Third Party

Company: Illumina, Inc.

Industry: Medical - Biomedical and Genetics

Record: 322

02/08/2012

Company Report

Pages: 10

4Q11 Recap - Strong Sequencing Rebound - Genotyping Light But Orders Encouraging

Provider: WEDBUSH SECURITIES INC.

Analyst: KHURSHID Z

Price: 25.00

Research Provided by a Third Party

Company: Illumina, Inc.

Industry: Medical - Biomedical and Genetics

Record: 323

01/25/2012

Company Report

Pages: 5

Roche Goes Hostile - Offers $44.50 per Share for ILMN: Likely Only an Opening Offer

Provider: AURIGA USA

Analyst: MCDONALD P

Price: 10.00

Research Provided by a Third Party

Company: Illumina, Inc.

Industry: Medical - Biomedical and Genetics

Record: 324

01/25/2012

Company Report

Pages: 8

Roche Initiates Hostile Bid for $44.50 - Not Enough Given Recent Progress & FCF Yield - Raising Estimates & PT from $35 to $50

Provider: WEDBUSH SECURITIES INC.

Analyst: KHURSHID Z

Price: 25.00

Research Provided by a Third Party

Company: Illumina, Inc.

Industry: Medical - Biomedical and Genetics

Record: 325

12/08/2011

Daily Note

Pages: 8

Maintaining LT OUTPERFORM But Less Optimistic on GMs Due To Higher Trade-In Discounting Data Point; MiSeq Delivery Delays Difficult To Interpret

Provider: WEDBUSH SECURITIES INC.

Analyst: KHURSHID Z

Price: 25.00

Research Provided by a Third Party

Company: Illumina, Inc.

Industry: Medical - Biomedical and Genetics

Record: 326

10/26/2011

Company Report

Pages: 5

3Q11 Results Review: Patience Should Be Rewarded

Provider: AURIGA USA

Analyst: MCDONALD P

Price: 10.00

Research Provided by a Third Party

Company: Illumina, Inc.

Industry: Medical - Biomedical and Genetics

Record: 327

10/25/2011

Company Report

Pages: 10

3Q11 Results Roughly In-line - Solid GMs and Cash Flow - Increasing Backlog - Sample Access Issue Still Murky - Maintaining OUTPERFORM.

Provider: WEDBUSH SECURITIES INC.

Analyst: KHURSHID Z

Price: 25.00

Research Provided by a Third Party

Company: Illumina, Inc.

Industry: Medical - Biomedical and Genetics

Record: 328

10/24/2011

Company Report

Pages: 7

3Q11 Preview - Sequencer Utilization & Operating Leverage Under Scrutiny

Provider: WEDBUSH SECURITIES INC.

Analyst: KHURSHID Z

Price: 25.00

Research Provided by a Third Party

Company: Illumina, Inc.

Industry: Medical - Biomedical and Genetics

Record: 329

10/07/2011

Company Report

Pages: 7

Lowering PT to $35 from $78 After Big 3Q11 Whiff on Budget-Driven Sequencing Slowdown

Provider: WEDBUSH SECURITIES INC.

Analyst: KHURSHID Z

Price: 25.00

Research Provided by a Third Party

Company: Illumina, Inc.

Industry: Medical - Biomedical and Genetics

Record: 330

10/07/2011

Company Report

Pages: 5

Ugly 3Q Preannouncement as Funding Environment Weighs; Reducing Estimates and Target

Provider: AURIGA USA

Analyst: MCDONALD P

Price: 10.00

Research Provided by a Third Party

Company: Illumina, Inc.

Industry: Medical - Biomedical and Genetics

Record: 331

09/01/2011

Daily Note

Pages: 8

Maintaining OUTPERFORM Thesis Following Wedbush Life Science Tools Bus Tour

Provider: WEDBUSH SECURITIES INC.

Analyst: KHURSHID Z

Price: 25.00

Research Provided by a Third Party

Company: Illumina, Inc.

Industry: Medical - Biomedical and Genetics

Record: 332

07/27/2011

Company Report

Pages: 5

2Q11 Results Review: Great Quarter and Solid Guidance Run Head on Into Even Greater Expectations

Provider: AURIGA USA

Analyst: MCDONALD P

Price: 10.00

Research Provided by a Third Party

Company: Illumina, Inc.

Industry: Medical - Biomedical and Genetics

Record: 333

07/27/2011

Company Report

Pages: 10

Reaffirming OUTPERFORM- Buyers on the Selloff-PT Down a Smidgen to $78

Provider: WEDBUSH SECURITIES INC.

Analyst: KHURSHID Z

Price: 25.00

Research Provided by a Third Party

Company: Illumina, Inc.

Industry: Medical - Biomedical and Genetics

Record: 334

07/25/2011

Company Report

Pages: 7

Reaffirming OUTPERFORM Rating Ahead of 2Q11 Earnings

Provider: WEDBUSH SECURITIES INC.

Analyst: KHURSHID Z

Price: 25.00

Research Provided by a Third Party

Company: Illumina, Inc.

Industry: Medical - Biomedical and Genetics

Record: 335

04/27/2011

Company Report

Pages: 5

1Q11 Results Review-We are assuming coverage with a Buy rating and a $75 price

Provider: AURIGA USA

Analyst: MCDONALD P

Price: 10.00

Research Provided by a Third Party

Company: Illumina, Inc.

Industry: Medical - Biomedical and Genetics

Record: 336

04/27/2011

Daily Note

Pages: 4

PACB 1Q11 Highlights

Provider: WEDBUSH SECURITIES INC.

Analyst: KHURSHID Z

Price: 10.00

Research Provided by a Third Party

Company: Illumina, Inc.

Industry: Medical - Biomedical and Genetics

Record: 337

04/27/2011

Company Report

Pages: 10

Rock Solid 1Q11 Beats on Strong Systems & Consumables; Likely To Be More Where That Came From; Raising PT to $80 from $75

Provider: WEDBUSH SECURITIES INC.

Analyst: KHURSHID Z

Price: 25.00

Research Provided by a Third Party

Company: Illumina, Inc.

Industry: Medical - Biomedical and Genetics

Record: 338

04/25/2011

Company Report

Pages: 8

1Q11 Financial Preview; Instrument Placements Likely Good; Possible Play on 2007 Utilization Redux; Improving Psychology Too

Provider: WEDBUSH SECURITIES INC.

Analyst: KHURSHID Z

Price: 25.00

Research Provided by a Third Party

Company: Illumina, Inc.

Industry: Medical - Biomedical and Genetics

Record: 339

04/13/2011

Company Report

Pages: 8

Competition Update: GnuBIO Making Noise

Provider: WEDBUSH SECURITIES INC.

Analyst: KHURSHID Z

Price: 25.00

Research Provided by a Third Party

Company: Illumina, Inc.

Industry: Medical - Biomedical and Genetics

Record: 340

03/28/2011

Company Report

Pages: 5

Pullback Creates Opportunity to Own NGS Leader - Upgrading to Buy and Reiterating $75 PT

Provider: AURIGA USA

Analyst: MEHRA R

Price: 10.00

Research Provided by a Third Party